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ABSTRACT 21 
 22 
Treatment for hepatitis C virus (HCV) has improved greatly through the use of direct acting antivirals 23 
(DAAs). However, their effectiveness and potential for drug resistance development in non-genotype 24 
1 variants of HCV remains relatively unexplored as in vitro assays to assess drug susceptibility are 25 
poorly developed and unsuited for a transient transfection format. In the current study, we have 26 
evaluated effects of dinucleotide frequency changes in the replicon and the use of a SEC14L2-27 
expressing cell line on the replication of HCV of different genotypes and evaluated the resulting 28 
assay formats for susceptibility measurements to the DAA, Sofosbuvir. Removal of CpG and UpA 29 
dinucleotides from the luciferase gene used in HCV replicons of genotype 1b (Con1) and 2a (JFH-1) 30 
achieved between 10-100-fold enhancement of replication over wild type post transfection. 31 
Removal of CpG/UpA-high neomycin genes in replicons of genotype 3a (S52) and 4a (ED43) 32 
enhanced replication but phenotypic effects on altering luciferase gene composition were minimal. 33 
Further ten-fold replication enhancement of replicons from all four genotypes was achieved using a 34 
transgenic Huh7.5 cell line expressing SECL14L2, whose expression showed a dose-dependent effect 35 
of HCV replication that was reversible by siRNA knockdown of gene expression. Combining these 36 
strategies, the 100 to 1000-fold enhancement of replication allowed susceptibility to the RNA 37 
polymerase inhibitor, Sofosbuvir, in a transient transfection assay format to be robustly determined 38 
for all four genotypes. These methods of replication enhancement provide new tools for the 39 
monitoring of susceptibility and resistance of a wide range of HCV genotypes to DAAs.  40 
 41 
 42 
 43 
44 
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INTRODUCTION 45 
 46 
Hepatitis C virus (HCV) is a positive-sense RNA virus of the Flaviviridae family first described in 1989 47 
(1) and subsequently identified as the principal cause of non-A, non-B hepatitis in blood recipients 48 
and haemophiliacs, as well as widely infecting injecting drug users (2,3). Based on meta-analysis of 49 
serological data it is estimated that about 185 million people worldwide are infected with HCV (4). 50 
Currently there are 7 genotypes of HCV recognised of which genotype 1 accounts for 46.2% of all 51 
infections, followed by genotype 3 with 30.1% and genotypes 2, 4 and 6 for 22.8% (5). It is estimated 52 
that 70-80% of all new infections progress to chronicity that can ultimately lead to end-stage liver 53 
disease (6,7).  54 
Until recently, HCV was treated by combination-therapy of pegylated interferon-α and the 55 
nucleoside inhibitor Ribavirin which is effective in genotypes 2 and 3 infections (approximately 80% 56 
sustained virological response), but less so in genotypes 1 and 4, where 50% or less achieve virus 57 
clearance (8-10). The phenotypic diversity of HCV genotypes, as manifested by these major 58 
differences in treatment response therefore requires the effectiveness of and resistance 59 
development to novel antiviral treatments to be evaluated separately for different HCV genotypes 60 
and subtypes. Such testing is generally performed using subgenomic replicons in which the 61 
structural genes are replaced by a luciferase or other reporter gene to allow replication to be rapidly 62 
quantified (11,12). However, most wild-type replicons replicate poorly in cell culture and generally 63 
restricted to the Huh7.5 cell line in which a number of cellular defence pathways are non-functional, 64 
including the cytosolic RNA receptor, RIG-I (13). However, under antibiotic selection for replicon-65 
containing cells, stable cell lines can be selected in which replicons rapidly acquire cell culture 66 
adaptive mutations that enhance replication. For example, in the genotype 1b Con 1 replicon, 67 
adaptive mutations occur in the NS3, NS4B and NS5A genes (12,14,15) that may enhance HCV 68 
protein-protein interactions and viral morphogenesis, although the mechanisms remains poorly 69 
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understood (16). Such mutants, however, show increases in viral RNA in transient replication assays 70 
without antibiotic selection. Although there now exist a wide range of stably transfected Huh7.5 cell 71 
lines containing replicons of different HCV genotypes, the existence of functionally poorly defined 72 
adaptive mutations has the potential to influence their susceptibility to directly acting antivirals 73 
(DAAs) and effects of DAA-associated mutations on antiviral susceptibility. While transient 74 
replication assays are clearly preferable for such testing, many of the currently available replicons do 75 
not have the required level of replication needed in this assay format to accurately estimate changes 76 
in replication levels in drugs inhibition studies  77 
In the current study, we have investigated the effectiveness of two novel approaches to enhance 78 
HCV replication in cell culture. The first approach is to reduce frequencies of CpG and UpA 79 
dinucleotides in the reporter gene of HCV replicons to enhance replication. The rationale is based on 80 
previous studies that demonstrate that lowering CpG and UpA frequencies in coding regions of 81 
echovirus 7 or the luciferase gene in a derived replicon substantially enhanced their replication over 82 
wild type virus (17,18). A second, separate approach is based upon the recent finding that 83 
expression of the SEC14L2 gene is a limiting factor in HCV cell culture replication and enhancement 84 
of HCV replication was achieved through the use of cell lines that overexpressed the SEC14L2 gene, 85 
increasing the number of colony forming units in antibiotic-selected non-transient replicon studies 86 
(19).  87 
 88 
 89 
MATERIALS AND METHODS 90 
 91 
Replicon construction, RNA in vitro transcription and translation. The Con1 subgenomic replicon 92 
was provided by R. Bartenschlager (11), SGR-JFH1 and SGR-JFH1/GND were provided by J. 93 
McLauchlan (20), S52/SG-Feo (AII) and ED43/SG-Feo (VYG) were obtained from C. Rice (21). A 94 
synthetic DNA sequence used to replace the wild type (WT) luciferase sequence was specified using 95 
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the program Sequence Mutate in the SSE package (22) and was cloned in the various replicons using 96 
unique restriction sites at the 5‘ end (AscI) and 3’ end (PmeI) of the luciferase coding sequence (Fig. 97 
1).  98 
Replicon plasmids were linearized with XbaI, Mung-bean nuclease treated, purified, quantified and 99 
used as template for in vitro RNA transcription (MEGAscript, Invitrogen). RNA was precipitated using 100 
LiCl, washed, resuspended in water, aliquoted and stored at -80°C. 101 
Transcript RNAs (125 ng) were used in nuclease-treated rabbit reticulocyte lysate translation assays 102 
(Promega)  to compare the translation speed of the different luciferase constructs according to the 103 
manufacturer’s instructions. Samples were taken after 30 minutes incubation and the luciferase 104 
expression quantified as described below. 105 
Cell lines, electroporation and luciferase quantification. Huh7.5 cells were maintained in Dulbecco's 106 
modified Eagle's medium (DMEM; Invitrogen) supplemented with 4,500 mg/l glucose, 2 mM L-107 
glutamine, 10% heat-inactivated foetal calf serum (FCS; Harlan Sera-Lab), nonessential amino acids, 108 
20 mM HEPES, 100 U/ml penicillin, and 100 μg/ml streptomycin and incubated at 37°C, 5% CO2, and 109 
100% relative humidity. 110 
For electroporation, cells were washed 3x in cold PBS, counted and diluted to 107 cells/ml. Using 111 
4mm electroporation cuvettes, 400μl of the cell suspension was mixed with 1 μg of replicon RNA and 112 
electroporated (at 270V, 950μF) using the exponential setting in an electroporator (Bio-rad, 113 
Genepulser XCell). Cells were immediately resuspended in warm, complete DMEM and transferred 114 
to the appropriate sized cell culture dishes. At the desired time points, medium was removed, the 115 
cells washed with PBS and lysed in passive lysis buffer (Promega) and the luciferase expression 116 
measured using the ‘Steady-glo’ assay system (Promega) and a luminometer (Promega, Glomax 117 
Multi detection system). 118 
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To obtain stable cell lines expressing SEC14L2, a lentiviral vector expressing this gene (Applied 119 
Biological Materials) was used to generate lentiviruses according to the manufacturer’s instructions. 120 
Huh7.5 cells were transduced with the lentivirus particles and selected with 5 μg/ml of puromycin. 121 
Single colonies were isolated and grown for further evaluation.  122 
Protein isolation and Western blotting. Cell monolayers were washed with PBS before being lysed 123 
in RIPA buffer (50mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate and 1% Triton-X100), 124 
mixed with sample buffer (Sigma, Laemmli 2x concentrate) and boiled for 10 minutes. Protein 125 
samples were loaded on 10% gels (Bio-rad, mini-protean TGX), transferred by semi-dry blotting to 126 
Immobilon paper (Millipore) and blocked in 5% milk-powder in PBS. After washing in PBS-T (PBS with 127 
0.05% Tween), blots were probed with anti-SEC14L2 (Santa Cruz Biotechnology) or anti β-tubulin 128 
(Abcam) as a loading control for one hour at room temperature, washed and probed with anti-129 
mouse HRP or anti-rabbit HRP respectively, for one hour at room temperature, washed and 130 
developed using ECL (ECL prime, Amersham). 131 
siRNA transfection. Knockdown of SEC14L2 was performed using the commercially available and 132 
validated esiRNA, EHU146781 (Sigma-Aldrich). The irrelevant siRNA sequences used as a control was 133 
obtained from the same manufacturer (EHUEGFP). To knock-down SEC14L2 expression in the stable 134 
cell line, a titration of SEC14L2-specfic siRNA was performed by transfecting 0, 100, 200 and 400 ng 135 
of siRNA/ 24-well using Lipofectamine RNAiMAX transfection reagent (Invitrogen) using the 136 
manufacturer’s instructions. Mock treated cells received 400 ng of validated non-targeted control 137 
siRNA. After 48 hours, SEC14L2 expression levels were quantified by Western-blot and ImageJ 138 
software.  139 
Sofosbuvir susceptibility testing. For the titration of Sofosbuvir (PSI-7977, Cayman chemical), cells 140 
were electroporated with replicon RNA and seeded at the required density. After 4 hours the 141 
medium was replaced with DMEM containing the desired concentration of Sofosbuvir dissolved in 142 
Witteveldt et al., AAC02932-1 - revised) 
Page 7/26 
ethanol or mock treatment control (ethanol) and refreshed every 24 hours to ensure a constant 143 
Sofosbuvir presence in the medium. 144 
qRT-PCR. SEC14L2 mRNA expression levels were quantified by qRT-PCR using the forward primer: 5’-145 
TGCAGTGATCCTGGCATCTATG-3’ and reverse: 5’-TGAGGCTTTGTCTGGAAGCAG-3’. RNA was extracted 146 
using the RNeasy kit (Qiagen), DNAse-treated and reverse transcribed using GoScript reverse 147 
transcriptase (Promega). The qRT-PCR was performed in a Rotorgene real-time PCR cycler (Qiagen) 148 
using the SensiFAST sybr kit (Bioline) and GAPDH for normalization (Forward 5’-149 
GAAATCCCATCACCATCTTCCAGG-3’; Reverse 5’-GAGCCCCAGCCTTCTCCATG-3’). RNA stability of the 150 
different replicons was determined by measuring luciferase-RNA levels at four hours post 151 
electroporation by qPCR (Forward 5’- CCCTGGTTCCTGGAACAATTGC-3’ and Reverse 5’-152 
AAGAATTGAAGAGAGTTTTCACTGC-3’).   153 
 154 
 155 
RESULTS 156 
 157 
Effect of CpG/UpA dinucleotide composition on the replication of HCV replicons.  In its unmodified 158 
state, the genotype 2a replicon (JFH1) already shows a robust level of replication in a number of cell 159 
lines, without any need for cell-culture adaptive mutations (20, 23, 24). We used the JFH1 replicon 160 
expressing the firefly luciferase gene driven by the HCV 5’ UTR (20). The WT luciferase sequence 161 
shows a striking elevation of the observed to expected frequency of CpG dinucleotides (1.21; Table 162 
1) compared to that in HCV (0.71 – 0.74 in genotypes 1-6) and in human mRNA sequences (mean 163 
0.43). High frequencies of this dinucleotide and UpA substantially restricted the replication of 164 
echovirus 7 (17) and we reasoned this may also influence the replication capability of the HCV 165 
replicons in mammalian cell culture. We therefore replaced the wild type luciferase gene (L) in JFH1 166 
with the CpG/UpA-low mutant (l) in both the replication-competent (GDD) and replication 167 
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incompetent background (GND). The modified luciferase sequence was mutated to remove all 100 168 
of the CpG dinucleotides present in the native sequence and 64 of the 86 UpA dinucleotides, the 169 
maximum possible while retaining identical amino acid coding to the WT sequence (Table 1; Fig. 1A). 170 
The modified sequence, however, contained a similar G+C content, codon adaptation index (CAI) 171 
and codon pair bias (CPB) to the WT sequence. 172 
Genotype 2a replicons with WT and CpG/UpA-low luciferase reporter genes (2a/l-GDD and 2a/L-GDD 173 
respectively) were transfected into Huh7.5 cells and luciferase expression quantified at different 174 
time points post-electroporation (Fig. 2A). To ensure equal amounts of RNA were delivered in the 175 
cells, an aliquot of cells were taken 15 minutes after electroporation, RNAse-treated to remove 176 
extracellular RNA and the internalized luciferase-RNA quantified by qRT-PCR. No significant 177 
differences in amounts of RNA were found between the different mutants used was observed (data 178 
not shown). Despite this equal delivery of RNA, the replication kinetics of the 2a/L-GDD (original) 179 
and 2a/l-GDD (CpG/UpA-minimised) were distinct with an approximate hundred-fold (2-log) 180 
difference in luciferase expression at 48 hours and 96 hours. This difference was greater than the 5-181 
fold-difference in luciferase gene expression 4 hours post-transfection and at earlier time points 182 
before significant replication of HCV had taken place (Fig. S1; Supplementary Data).  183 
The same changes were also made in the genotype 1b background, using the Con1 subgenomic 184 
replicon (1b/L-GDD, 1b/l-GDD and replication defective counterparts, 1b/L-GND, 1b/l-GND; Fig. 2B). 185 
Unlike the 2a replicons, the WT (1b/L-GDD) replicon showed very poor replication levels in Huh7.5 186 
cells (Fig. 2B) in the first 24 hours. RT-qPCR analysis confirmed that comparable amounts of RNA 187 
were electroporated in the cells at one hour (data not shown). Similarly, from 24 hours, their 188 
replication kinetics were distinct, where the low-CpG/UpA luciferase replicon showed a greater than 189 
2-log higher luciferase levels at 96 hours post electroporation compared to 1b/L-GDD.  190 
To investigate effects of dinucleotide composition changes for other genotypes, a range of replicons 191 
were constructed using genotype 3a (S52/SG-Feo(AII)) and 4a (ED43/SG-Feo (VYG)) backbones 192 
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(Saeed et al. (21)). The original replicons expressed luciferase as a fusion with neomycin (N) which 193 
also possesses high frequencies of CpG and UpA dinucleotides (Fig. 1B). Mutants were constructed in 194 
which luciferase was replaced with the CpG/UpA-low sequence (3a/lN-GDD and 4a/lN-GDD), those 195 
with deletion of the neomycin gene (3a/L-GDD and 3a/L-GND) and a combination of CpG/UpA-low 196 
luciferase sequences and neomycin deletion (3a/l-GDD and 4a/l-GDD).  197 
Both of the original replicons, 3a/LN-GDD and 4a/LN-GDD, of genotypes 3 and 4 replicated poorly in 198 
transient replication assays compared to genotype 2a (Figs. 1C, 1D). In contrast to previous 199 
experiments using 1b and 2a-based replicons, replacing the luciferase sequence in genotype 3 200 
(3a/lN-GDD) did not enhance replication. However, deletion of the neomycin sequence in the 3a/L-201 
GDD increased replication compared to 3a/LN-GDD, although this effect was not reproduced in the 202 
low luciferase version of the neomycin-deleted construct (3a/l-GDD). For genotype 4, deletion of the 203 
neomycin gene (4a/L-GDD) and introduction of low-CpG/UpA luciferase (4a/lN-GDD) both enhanced 204 
replication over the original replicon (4a/LN-GDD), effects that were synergistic at early time points 205 
(4a/l-GDD).  For all genotype 3 and 4 replicon mutants, quantitiation of transfected RNA at one hour 206 
demonstrated that comparable amounts of RNA were electroporated into the cells (data not 207 
shown). 208 
Effect of SEC14L2 expression on HCV replication. To investigate whether the reported enhancement 209 
of replication by expression of SEC14L2 (19) could also be achieved in a transient transfection 210 
replication assay, a number of clonal cell-lines stably expressing SEC14L2 were made. Based on 211 
SEC14L2 expression levels measured by RT-qPCR, several lines were selected and tested for SEC14L2 212 
proteins expression levels by Western blot (Fig. 3A). All five cell lines selected constitutively 213 
expressed detectable but variable levels of SEC14L2 protein while it was undetectable in the 214 
parental Huh7.5 cell line (labelled “P”).  215 
Three out of five cell lines supported enhanced replication of 1b/L-GDD replicon (Fig. 3B), with cell 216 
line #23 showing the highest increase in replication compared to the parental cell line 217 
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(approximately x25-fold). To verify this replication enhancement arose directly from increased 218 
expression of SEC14L2 and was not an artefact introduced the transduction and consequent single 219 
cell selection, siRNA was transfected in #23 cells to knock-down SEC14L2 protein expression (Fig. 220 
3C). The effect of SEC14L2 knockdown on HCV replication was investigated in cells transfected with a 221 
siRNA concentration that achieved a 75% knock-down of expression (Fig. 3D). These cells were 222 
electroporated with 1b/l-GDD, and luciferase expression measured compared to mock-treated #23 223 
cells (Fig. 3D). Knock down SEC14L2 decreased replicon replication by approximately 4-fold at 72 224 
hours, confirming the involvement of SEC14L2 in the control of replicon replication. 225 
Replication of HCV genotypes 1-4 in SEC14L2-expressing cells. Replicons with all four genotype 226 
backbones and corresponding CpG/UpA-low luciferase mutants were electroporated into the 227 
SEC14L2 expressing cell line #23 and replication compared to that of the parental Huh7.5 cells (Fig. 228 
4). Replication of the 2a/L-GDD replicon was increased approximately 17-fold in the SEC14L2 229 
expressing cell line at the 72 h.p.e. time point; a slightly lower enhancement was observed in the 230 
2a/l-GDD (CpG/UpA-low) construct (Fig. 4A). Replication enhancement was synergistic, with a 340-231 
fold increase in luciferase expression in 2a/l-GDD in #23 cells compared to 2a/L-GDD in Huh7.5 cells. 232 
Consistent with a role for SEC14L2 expression in enhancing replication, luciferase expression from 233 
both 2a/L-GND and 2a/l-GND defective replicons was comparable between cell lines (Fig. 4A). 234 
A comparable 10-fold enhancement of the replication of the Con1 1b/L-GDD and 1b/l-GDD replicons 235 
was observed in #23 cells, with similarly no effect on their replication defective counterparts (Fig. 236 
4B). SEC14L2 expression and lowering CpG/UpA frequencies had a synergistic effect, leading to an 237 
overall 1200-fold replication enhancement compared to the original replicon in Huh7.5 cells. 238 
Replicons based on genotype 3a and 4a backbones (3a/L-GDD and 4a/L-GDD) showed approximately 239 
1-log increased luciferase expression. A much larger cell line-dependent increase was observed in 240 
the Neomycin-deleted 3a replicon, 3a/l-GDD (Figs. 3C, 3D).  241 
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Mechanism of replication enhancement. The increased replication of replicons with alterations to 242 
dinucleotide composition may have originated from differences in the efficiency of translation of the 243 
luciferase gene through associated alterations in codon usage or codon pair bias (25-27). 244 
Alternatively, as demonstrated for E7, changes in CpG and UpA frequency may influence the cellular 245 
response to infection and induce greater restriction of replication (17). To investigate effects of CpG 246 
and UpA dinucleotide frequency changes on translation, replicons from all four genotypes containing 247 
the original (L) or modified (l) luciferase genes were assayed for translation efficiency in an in vitro 248 
translation assay (Fig. 5). Despite the large differences in codon usage and codon pair bias between 249 
the insect-derived luciferase gene and the CpG/UpA-minimised mutant sequence (Table 1), 250 
expression of the original and mutant forms of the luciferase gene in all four replicons of genotypes 251 
1-4 was similar. The two forms of luciferase gene showed at most 2-fold differences in translation 252 
efficiency but with no evidence for any consistent greater expression of the CpG/UpA-low luciferase 253 
sequences over wild type (Fig. 5). To ensure the assay was not saturated with RNA that narrowed 254 
differences in expression, the assay was repeated using different RNA transcript amounts. 255 
Transfecting 4 times more and four times less RNA confirmed that the read-outs for the assay 256 
concentrations used were in the linear range (Fig. S2; Supplementary Data).  257 
Replicons containing modified luciferase gene sequences showed comparable stability post-258 
transfection. In the absence of replication, RNA levels of both genotype 1 and 2a replicons showed a 259 
comparable at 4 hours post-transfection (Fig. S3; Supplementary Data).     260 
As the restriction in replication engendered by increased frequencies of CpG and UpA dinucleotides 261 
composition was not mediated though differences in translation efficiency or greater RNA instability, 262 
we next investigated whether the inhibition of replication in replicons expressing native (high 263 
CpG/UpA) luciferase genes was mediated on the replicon containing the gene sequence (in cis) or 264 
induced a global change in the dell in permissivity to HCV replication (in trans). 1b/L-GDD and 1b/l-265 
GDD (containing WT- and CpG/UpA-low luciferase gene sequences respectively) were co-266 
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electroporated into Huh7.5 cells (Fig. 6A). The presence of 1b/L-GDD RNA minimally reduced the 267 
replication of 1b/l-GDD (approximately 50%) compared to expression levels of 1b/l-GDD 268 
electroporated alone. The experiment was repeated in the SEC14L2 expressing cell line, where no 269 
effect on the expression of luciferase compared to electroporation on 1b/l-GDD alone (Fig. 6B). 270 
These findings provide evidence that effects of dinucleotide composition are mediated locally (in cis) 271 
on the RNA molecule possessing the altered dinucleotide composition rather than such sequence 272 
inducing a whole cellular restriction on replication (eg. mediated through induction of interferon-β).  273 
Use of enhanced transient transfection assays to measure susceptibility to DAAs. For testing the 274 
inhibitory capacity of HCV antiviral agents in transient replication assays, achieving sufficient 275 
replication levels to quantify degrees of inhibition is essential. We therefore investigated whether 276 
the enhanced replication achieved by replacing the wild-type luciferase or culture in SEC14L2-277 
expressing cell line facilitated the evaluation the NS5B inhibitor Sofosbuvir in genotypes 1b, 3a and 278 
4a. Cells were electroporated with each replicons in the presence of a range of Sofosbuvir 279 
concentrations spanning the previously established IC50 concentration (28,29). Luciferase expression 280 
levels were measured at time points 48, 72 and 96 hours post electroporation. Non-replicating 281 
replicons were included as baseline levels of luciferase expression. The 1b/L-GDD and 4a/L-GDD 282 
replicons replicated at such low levels in the Huh7.5 cell lines that replication inhibition by 283 
Sofosbuvir could not be detected (Fig. 7, left two panels). However, performing the assay in SEC14L2 284 
expressing cells improved the replication and enabled a concentration-dependent inhibition of 285 
replication by sofosbuvir to be detected (Fig. 7A/7C, panels 7-9). A major enhancement was 286 
observed using the 1b/l-GDD replicon in Huh7.5 cells which improved even more when using 287 
SEC14L2 expressing cells. This same pattern, but to a lesser extent was observed in genotype 4a. 288 
Although the wild type genotype 3a replicon already shows usable titration data in Huh7.5 cells, 289 
removal of Neomycin and especially the use of SEC14L2 expressing cells improved overall replication 290 
and enabled a robust estimation of IC50 values for sofosbuvir for this genotype (Table 2).  291 
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DISCUSSION 292 
 293 
Despite only reproducing the intracellular replication steps of the HCV lifecycle, replicons are a 294 
valuable tool in HCV research, especially in drug discovery programs and have been instrumental in 295 
the discovery of the first direct-acting antivirals (DAAs) (30), including Sofosbuvir (31), Simeprevir 296 
(32,33) and Boceprevir (34). In addition to susceptibility testing, in vitro systems play an essential 297 
role in monitoring the phenotypic effects of resistance-associated mutations that arise during DAA 298 
treatment on drug susceptibility (35,36). Resistance mutations are frequently genotype-specific and 299 
for their effects to be quantified, inhibition assays require that these mutations should be tested in 300 
the same genotypic background in vitro. DAA susceptibility and resistance testing should also be 301 
performed without the confounding effect of unpredictable cell-culture adaptive mutations that are 302 
likely to arise with antibiotic selection.  303 
To date however, most information on susceptibility and resistance testing has been based on in 304 
vitro assays using cell lines stably expressing HCV replicon-RNA, typically H77 (genotype 1a) and 305 
Con1 (genotype 1b) (36). Selection of stable cell lines prior to testing is also normally used in the 306 
analysis or selection of resistance mutations (38-40). However, construction of stably transformed 307 
cell lines is a time-consuming procedure and which is also likely to introduce additional cell culture 308 
adaptive mutations that may also influence DAA susceptibility, complicating the comparison with the 309 
wild-type replicons. Therefore the use of a transient expression assay with a range of genotypes 310 
would be highly advantageous in terms of speed, simplicity and avoidance of cell culture-induced 311 
artefacts. Although some of these have been used in the analysis of, for example, several resistance-312 
associated mutations to Sofosbuvir (29), the low level of replication generally achieved means that 313 
such studies are problematic to extend for a wider range of HCV strains and genotypes.  314 
To improve the replication of replicons in transient expression assays we first replaced the wild-type 315 
luciferase gene with a mutated version in which all CpG dinucleotides were removed and as many 316 
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UpA dinucleotides as possible while retaining the same coding sequence and similar codon usage. In 317 
both genotypes 1b (Con1) and 2a (JFH1), this replacement resulted in 2-log improved replication 318 
rates compared to replicons containing the original wild type luciferase sequence (Figs. 1A and 1B). 319 
This enhancement of replication was comparable to that exhibited in the echovirus replicon with 320 
similar replacement of the luciferase gene (17). How this enhancement of both initial gene 321 
expression and subsequent increased replication is mediated remains uncertain, although 322 
observation in the current study can rule out some mechanisms. Firstly, the absence of any 323 
consistent difference in translation efficiency of original and modified luciferase genes in different 324 
replicon constructs clearly demonstrates that the enhancement of replication of CpG/UpA-low 325 
replicons was not mediated though a translational mechanism. These findings are consistent with 326 
previous studies demonstrating comparable translation efficiency of mutants of E7 with regions of 327 
genome with altered dinucleotide frequencies and codon pair bias (18), and of poliovirus in which 328 
relatively small differences in translation rates between PV-Min, WT and PV-Max mutants differing 329 
in codon pair usage / dinucleotide frequencies were not predictive of their replicative ability (26). A 330 
detailed investigation of a range of compositional variables on the replication of poliovirus reported 331 
that CpG and UpA dinucleotide frequencies primarily influenced the replication of poliovirus, and 332 
was unaffected by variation in codon usage, codon pair bias and other metrics of predictive of 333 
translational optimisation, such as CAI (27). Modification of codon pair bias and CpG/UpA 334 
dinucleotide frequencies in echovirus 7 similarly indicated the primary influence of dinucleotide 335 
frequencies on virus replication (18). In a broader context, differences in expression of the luciferase 336 
gene mediated purely through translational effects cannot contribute to the replication fitness of 337 
HCV replicons as its purpose is simply to act as reporter gene. The enhancement of replication of 338 
replicons containing CpG/UpA-low luciferase coding sequences must therefore be mediated though 339 
alternative mechanisms.  340 
The minimal or absent interference on replication of the 1b/l-GDD by the wild type 1b/L-GDD 341 
replicon similarly argues against a global restriction in permissivity for viral replication that would be 342 
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expected in interferon-primed cells. The lack of interference between replicons is however 343 
compatible with the hypothesis advanced previously to explain the restriction of CpG/UpA-high 344 
mutants of E7. In this account, possession of high CpG and UpA dinucleotides may induce a localised 345 
stress response in the cell that influences the ability of viruses to establish replication complexes 346 
(17). The HCV replicon system established in the current study provides a valuable tool for future 347 
dissection of the restriction mechanisms associated with altered dinucleotide frequencies   348 
The clear replication enhancement observed in the genotype 1b and 2a replicons containing 349 
CpG/UpA-low luciferase sequence was not fully reproduced in genotypes 3a and 4a, but showed a 350 
more subtle and complicated pattern. The original versions of both replicons expressed luciferase as 351 
a fusion protein with neomycin (21). Removal of neomycin in genotype 3a increased replication 352 
although in contrast to other replicons, replacement of the luciferase component of the fusion 353 
protein with the CpG/UpA-low sequence negatively impacted replication of the genotype 3a replicon 354 
(Fig. 2C) for reasons that remain undetermined. In the genotype 4a replicon, removal of the 355 
neomycin gene similarly resulted in enhanced replication at late time points but in this case the 356 
further introduction of the low CpG/UpA luciferase further increased replication to a similar degree 357 
to that observed in genotype 1b and 2a. Understanding how the restrictions in replication mediated 358 
though dinucleotide composition interact with the limited or complete inability of many genotype or 359 
strains of HCV to replicate in cell culture will require a much better understanding of the cellular 360 
pathways that mediate these replication phenotypes and their potential for interaction.  361 
As a further manifestation of the complexity of the restriction of HCV replication in vitro, substantial 362 
increases in the replication of replicons with all four genotype backgrounds were achieved in cells 363 
over-expressing SEC14L2. SEC14L2 was originally reported to enhance the replication of non-cell 364 
culture adapted isolates of HCV that are not resistant to lipid peroxidation (19). We investigated 365 
whether same positive effect on replication could be achieved for replicons in a transient expression 366 
assay format. Transduction of parental Huh7.5 cells and consequent selection yielded colonies with 367 
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varying levels of SEC14L2 mRNA- and protein expression (Fig. 3A). Knock-down of SEC14L2 by siRNA 368 
was used to confirm the involvement of this gene and not an artefact of transduction or selection 369 
(Figs. 2C and 2D). Transient expression assays of HCV replicons showed a broadly consistent ten-fold 370 
increase in replication in cells expressing high levels of SEC14L2 compared to the parental Huh7.5 371 
cell line with some higher (genotype 3a, neomycin-low CpG/UpA) and lower (genotype 4a, low 372 
CpG/UpA) exceptions (Figs. 4A-C). Expression of SEC14L2 had no effect on the expression of 373 
luciferase in replication-incompetent (GND) replicons, suggesting that SEC14L2 directly influenced 374 
replication rather than RNA stability and/or translation. However, in contrast to previously reported 375 
results (19), we observed a consistent and substantial increase in the replication in the lipid-376 
peroxidation resistant genotype 2a JFH1 replicon, whose replication was not enhanced in stably-377 
transfected cell lines. Differences in assay systems may have contributed to this difference; firstly 378 
our experiments were performed in a cell line with SEC14L2 expressed from a transgene that is not 379 
under the same regulatory control as the native gene. Secondly, we electroporated the cells instead 380 
of using transfection; this may deliver RNA at a different location and efficiency and influence the 381 
efficiency of initial translation and gene expression and consequent replication efficiency.  382 
Irrespective of the likely complex mechanisms underlying the restriction of HCV replication in cell 383 
culture, this study achieved its original goal of improving the replication of replicons that enable 384 
their use in transient expression assays. This enabled a pilot study of the susceptibility of different 385 
genotypes to the NS5B inhibitor Sofosbuvir (Fig. 7). The enhancement of replication in SEC14L2-386 
exressing cells and changing to the low CpG/UpA luciferase reporter gene enabled robust 387 
measurement of IC50s for genotypes 1-4 (Table 2), generating values that were comparable to those 388 
reported previously from other assay systems (28,29).  389 
In summary, we have shown that reducing the number of CpG and UpA dinucleotides in HCV 390 
subgenomic replicons can greatly enhance replication levels but with some variability between 391 
genotypes. Combined with further increases in HCV replication in cell expressing SEC14L2, the 30-392 
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1000-fold increases in replication achieved across all four genotypes will greatly facilitate 393 
susceptibility and resistance mutation testing in a convenient and rapid transient expression assay 394 
format.  395 
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TABLE 1 536 
Composition and coding parameters of WT and CpG / UpA-low luciferase sequences 537 
 538 
Sequence Symbol Subs.a C+G% CpG ΔCpG b O/E c UpA ΔUpA b O/E CAId CPS e
WT L --- 0.44 100 --- 1.21 86 --- 0.70 0.719 -.011
CpG/UpA-low l 174 0.45 0 100 0 22 64 0.17 0.804 0.021
 539 
aNumber of sequence changes from WT sequence 540 
bChange in the numbers of CpG and UpA dinucleotides 541 
cObserved to expected frequencies of CpG and UpA dinucleotides 542 
dCalculated using the website http://genomes.urv.es/CAIcal/ (41) 543 
eCalculated as previously described  (26,42) 544 
 545 
 546 
 547 
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 549 
TABLE 2 550 
IC50 values for Sofosbuvir in genotypes 1b (Con1), 3a (S52) and 4a (ED43) 551 
Cell Replicon 48 h.p.e.  72 h.p.e.  96 h.p.e. 
7.5 
1b/L-GDD -a - -
1b/l-GDD -  -  - 
3a/LN-GDD 48±4b 42.3±1.3 57±2 
3a/L-GDD 53±8  47.3±8.8  40±2 
4a/LN-GDD -  -  - 
4a/l-GDD -  -  49±27 
#23 
1b/L-GDD -  -  - 
1b/l-GDD 95±8  42±4  55±6 
3a/LN-GDD 35±3  38±6  29±1 
3a/L-GDD 42±3 41±2 29±1 
4a/LN-GDD -  -  28±10 
4a/l-GDD -  45±15  38.5±0.5 
 552 
a  - : Not determined (insufficient replication) 553 
bIC50 values are the concentration of Sofosbuvir that inhibits the replicon of the HCV replicon by 50% 554 
555 
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FIGURE LEGENDS 556 
 557 
Fig. 1. Structure of sub-genomic replicons and mutants. Diagrammatic representations of the 558 
replicons used in the current study, with changes to the luciferase gene (L, l), deletion of the 559 
neomycin gene (N) and replacement of the GDD motif in NS5B with GND to make it replication 560 
defective labelled.  561 
Fig. 2. Replication of unmodified replicons and mutants with low CpG/UpA luciferase. Replication of 562 
genotype (A) 2a, (B) 1b, (C)  3a and (D) 4a replicons after electroporation into Huh7.5 cells. 563 
Luciferase activity of was measured at four time points (x-axis) and plotted as the absolute values (y-564 
axis). Error bars represent standard deviations.  565 
Fig. 3. Expression of SEC14L2 in different cell lines and effect of HCV replication. (A) Quantification of 566 
SEC14L2 expression by western blot of cell lysates from different cell lines. P: parental Huh7.5 cell 567 
line. Samples were normalized to total amount of protein loaded; a conrol immunoblot using β-568 
tubulin is shown below (B) luciferase expression in different cell lines at different time points after 569 
electroporation of 1b/l-GDD. The values are normalised to luciferase expression of the 1b/l-GDD 570 
replicon in the parental Huh7.5 cell line at each time point. (C) Effect of transfection of SEC14L2-571 
specific siRNA in line #23 on SEC14L2 expression levels as determined by western blot (D) Replication 572 
of 1b/l-GDD in siRNA-treated and irrelevant siRNA-treated #23 cells. Error bars depict standard 573 
deviations.  574 
Fig. 4. Comparison of the replication of replicons from genotypes 1-4 in Huh7.5 and #23 cell lines. 575 
Replication of replicons from genotypes 1-4 generated in the study in Huh7.5 and #23 cell lines; right 576 
hand panels show luciferase expression from the replication incompetent control. Error bars depict 577 
standard deviations.   578 
Witteveldt et al., AAC02932-1 - revised) 
Page 26/26 
Fig. 5. In vitro translation assay of wild type and low CpG/UpA luciferase replicons. Measurement of 579 
luciferase activity of translation products of WT and CpG/UpA-low HCV replicons of genotypes 1-4 580 
after a 30 minute incubation time. Bars show the mean of two replicates; error bars show standard 581 
deviations.  582 
Fig. 6. Co-electroporation of CpG/UpA-low and WT luciferase containing replicons. Luciferase 583 
expression in (A) Huh7.5 cells and (B) #23 cells after electroporation of CpG/UpA-low, WT or both 584 
replicons; y-axis scale is normalised to luciferase expression by 1b/l-GDD (100%). Error bars depict 585 
standard deviations.   586 
Fig. 7. Susceptibility testing to Sofosbuvir of original and modified replicons. Inhibition of replication 587 
of CpG-low and WT luciferase replicons (A) 1b/l-GDD and 1b/L-GDD, (B) 3a/LN-GDD and 3a/L-GDD 588 
and (C) 4a/LN-GDD and 4a/l-GDD to differing concentration of Sofosbuvir. The experiment was 589 
performed in Huh7.5 and #23 cell lines. Error bars depict standard deviations.   590 
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